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ABSTRACT
Objective α-Conotoxin Vc1.1 is a small disulfide-
bonded peptide from the venom of the marine cone
snail Conus victoriae. Vc1.1 has antinociceptive actions
in animal models of neuropathic pain, but its
applicability to inhibiting human dorsal root ganglion
(DRG) neuroexcitability and reducing chronic visceral pain
(CVP) is unknown.
Design We determined the inhibitory actions of Vc1.1
on human DRG neurons and on mouse colonic sensory
afferents in healthy and chronic visceral hypersensitivity
(CVH) states. In mice, visceral nociception was assessed
by neuronal activation within the spinal cord in response
to noxious colorectal distension (CRD). Quantitative-
reverse-transcription-PCR, single-cell-reverse-
transcription-PCR and immunohistochemistry determined
γ-aminobutyric acid receptor B (GABABR) and voltage-
gated calcium channel (CaV2.2, CaV2.3) expression in
human and mouse DRG neurons.
Results Vc1.1 reduced the excitability of human DRG
neurons, whereas a synthetic Vc1.1 analogue that is
inactive at GABABR did not. Human DRG neurons
expressed GABABR and its downstream effector channels
CaV2.2 and CaV2.3. Mouse colonic DRG neurons
exhibited high GABABR, CaV2.2 and CaV2.3 expression,
with upregulation of the CaV2.2 exon-37a variant during
CVH. Vc1.1 inhibited mouse colonic afferents ex vivo
and nociceptive signalling of noxious CRD into the spinal
cord in vivo, with greatest efficacy observed during CVH.
A selective GABABR antagonist prevented Vc1.1-induced
inhibition, whereas blocking both CaV2.2 and CaV2.3
caused inhibition comparable with Vc1.1 alone.
Conclusions Vc1.1-mediated activation of GABABR is
a novel mechanism for reducing the excitability of
human DRG neurons. Vc1.1-induced activation of
GABABR on the peripheral endings of colonic afferents
reduces nociceptive signalling. The enhanced
antinociceptive actions of Vc1.1 during CVH suggest it is
a novel candidate for the treatment for CVP.
INTRODUCTION
IBS is a prevalent, chronic GI disorder that nega-
tively impacts the quality of life in up to 14% of
the population.1 2 It is characterised by abdominal
pain and discomfort associated with altered bowel
habits.3–5 Although the pathophysiology of IBS is
not completely understood, it is becoming clear
that changes to peripheral cellular and sensory
mechanisms play key roles in the associated pain.6 7
In particular, chronic visceral hypersensitivity
(CVH) of colonic afferents is implicated in the
development and maintenance of chronic visceral
Significance of this study
What is already known on this subject?
▸ Patients with IBS suffer from chronic visceral
pain (CVP); however, there are limited
analgesic therapeutic options currently
available for treatment.
▸ A rich source of novel agents to treat chronic
pain is the α-conotoxin family of peptides from
the venom of marine cone snails.
▸ α-Conotoxin Vc1.1 has antinociceptive and
antihyperalgesic actions in neuropathic pain
models; however, its ability to inhibit human
sensory dorsal root ganglion (DRG) neurons
remains unknown.
▸ Vc1.1’s applicability in reducing CVP is also
unknown.
What are the new findings?
▸ Vc1.1 reduces human sensory DRG
neuroexcitability, via a γ-aminobutyric acid
receptor B (GABABR)-mediated mechanism.
▸ We show that human DRG neurons express
GABABR and the voltage-gated calcium
channels CaV2.2, and CaV2.3, which are the
direct and downstream targets of Vc1.1,
respectively.
▸ Vc1.1 inhibits mouse colonic nociceptors and
also low-threshold distension-sensitive colonic
afferents with greatest effect during chronic
visceral hypersensitivity (CVH).
▸ Peripheral in vivo Vc1.1 administration inhibits
the signalling of noxious information from the
colon to the spinal cord. This antinociceptive
effect is also greater in mice with CVH.
▸ During CVH, mouse colonic DRG neurons show
upregulation of the CaV2.2 exon-37a variant,
which may explain the increased inhibitory
effect of Vc1.1 in CVH states.
1083Castro J, et al. Gut 2017;66:1083–1094. doi:10.1136/gutjnl-2015-310971
To cite: Castro J,  
Harrington AM, 
Garcia-Caraballo S, et al.  
Gut 2017;66:1083–1094.
► Additional material is 
published online only. To view 
please visit the journal online 
(http://dx.doi.org/10.1136/
gutjnl-2015-310971).
For numbered affiliations see 
end of article.
Correspondence to
Professor Stuart M Brierley, 
Visceral Pain Group, Centre for 
Nutrition and Gastrointestinal 
Diseases, The University of 
Adelaide, Level 7, South 
Australian Health and Medical 
Research Institute (SAHMRI), 
North Terrace, Adelaide, SA 
5000, Australia; stuart.brierley@
adelaide.edu.au
JC, AMH and SG-C contributed 
equally.
Received 27 October 2015
Revised 22 December 2015
Accepted 14 January 2016
Published Online First 
17 February 2016
Neurogastroenterology
group.bmj.com on June 8, 2017 - Published by http://gut.bmj.com/Downloaded from 
pain (CVP) in IBS.4 5 Characteristic features of CVH include
nociceptor hypersensitivity8 and increased signalling of noxious
colorectal distension (CRD) within the spinal cord.9–11 Recent
evidence suggests sensory afferents display upregulation of
numerous ion channels and receptors in animal models of
CVH,7 10 12 making them targets for analgesic treatment.
A recently introduced treatment for patients with IBS and
constipation involves a small disulfide-rich peptide that is
restricted to the GI tract, where it inhibits peripheral nociceptive
pathways and produces clinically relevant pain relief.9 Given the
limited treatments available for patients with other subtypes of
IBS, additional analgesic therapeutic options are needed. A rich
source of novel small disulfide-rich agents comes from the
α-conotoxin family of peptides from the venom of marine cone
snails.13 These peptides target a wide variety of membrane
receptors and ion channels.14 In particular α-conotoxin Vc1.1, a
16-amino acid synthetic version of a peptide derived from the
marine cone snail Conus victoriae, has antinociceptive actions in
vitro and antihyperalgesic actions in numerous in vivo neuro-
pathic pain models.15–17 Interestingly, in a chronic constriction
injury model of neuropathic pain, Vc1.1 relieves tactile allody-
nia.17 These inhibitory effects were similar to those obtained
with gabapentin, a ligand recently proposed as a potential IBS
therapeutic,18 but were achieved at far lower doses.17 Notably,
Vc1.1 (also called ACV1) has been used in phase I and phase
IIA clinical trials for the treatment of neuropathic pain.19–21
These studies showed Vc1.1 was safe and well tolerated with a
clean safety and side-effect profile. Despite this promise, thera-
peutic trials were discontinued as Vc1.1 was shown to be less
potent at the human α9α10 nicotinic acetylcholine receptor
(nAChR), which was thought to mediate the inhibitory action of
Vc1.1. However, more recent recombinant cell line studies
have clearly demonstrated that the human γ-aminobutyric acid
receptor B (GABABR) is the primary and high affinity target for
Vc1.1.17 22 25–27 These studies also demonstrated GABABR acti-
vation by Vc1.1 causes downstream inhibition of the voltage-
gated calcium channels CaV2.2 and CaV2.3, which underlies
Vc1.1’s inhibitory actions.14 28 These recent findings are intri-
guing; as both oral and intravenous administration of baclofen,
the archetypal GABABR agonist has been shown to reduce the
pseudo-affective responses to CRD in animal models.29 30
Although it is unclear if this baclofen-induced inhibition is cen-
trally or peripherally mediated, we wondered if Vc1.1 represents
a novel peripheral gut analgesic for the treatment of CVP.
Therefore, we determined if Vc1.1 inhibits human sensory
dorsal root ganglion (DRG) neurons, the primary transducers at
the start of the pain-processing pathway. Second, we determined
if Vc1.1 inhibits sensory pathways within the splanchnic and
pelvic innervation of the colon and whether these actions are
enhanced in an animal model of CVH. Third, we determined if
the inhibitory actions of Vc1.1 are mediated via activation of
GABABR on the peripheral endings of colonic afferents.
MATERIALS AND METHODS
For comprehensive descriptions of the methodologies used, see
the online supplementary information.
Human DRG
Thoracolumbar (TL) DRG (T9–L1) were acquired from five
(three female, two male) human adult organ donors (22.2
±2.08 years of age) during the removal of the vital organs for
transplantation. The harvested DRG were immediately pro-
cessed for downstream patch clamp or RNA studies. Intact
DRG were kept for quantitative-reverse-transcription-PCR
(qRT-PCR) mRNA expression studies from each spinal level
(T9, T10, T11, T12, L1) while additional DRG were dissociated
to allow individual DRG neurons to be studied with
single-cell-reverse-transcription-PCR (RT-PCR) studies, or to
allow patch clamp recordings to be performed.
Human DRG patch clamp recordings
Whole-cell patch clamp recordings of cultured human DRG
neurons were performed in current clamp mode in response to
depolarising current pulses (20 or 50 pA current steps, 500 ms
duration). This allowed the rheobase (amount of current needed
to initiate action potential generation) to be assessed in the pres-
ence and absence of Vc1.1 (1000 nM) and a synthetic analogue
of Vc1.1 ([P6O]Vc1.1;1000 nM), which is inactive at GABABR.
An increased rheobase indicates more current is required to fire
an action potential and therefore the neuron displays reduced
excitability.
Mouse model of CVH
Intracolonic trinitrobenzene-sulfonic acid (TNBS) was adminis-
tered as described previously.8–10 TNBS-treated mice were
allowed to recover for 28 days, at which stage inflammation had
resolved and chronic colonic afferent mechanical hypersensitiv-
ity was evident.8–10 12
Ex vivo electrophysiology
Recordings of splanchnic and pelvic afferents were made from
healthy control and CVH mice as described previously.8–10
Briefly, colonic nociceptors were recorded from the splanchnic
pathway. They respond to noxious distension (40 mm Hg),
stretch (≥7 g) or von Frey hair filaments (2 g)8 31 and become
mechanically hypersensitive in models of CVP.8–10 12 Muscular–
mucosal afferents were recorded from the pelvic pathway and
respond to both low-intensity circular stretch (<5 g) and fine
mucosal stroking (10 mg).8 31–33 Once baseline responses had
been established, mechanosensitivity was retested after applica-
tion of Vc1.1 (1, 10, 100, 1000 nM) for 10 min at each dose.
To determine the mechanism of action of Vc1.1 the selective
GABABR antagonist (CGP55845:5 μM), CaV2.2 blocker
(ω-conotoxin CVID:1 μM) or CaV2.3 blocker
Significance of this study
How might it impact on clinical practice in the
foreseeable future?
▸ Vc1.1 has been tested in human clinical trials for the
treatment of neuropathic pain, where it has been
demonstrated to have a clean safety and side-effect profile.
▸ Our current findings show Vc1.1 inhibits human DRG
neurons, via activation of the GABABR, which is a key
finding for clinical translatability.
▸ This inhibitory effect in human neurons combined with the
enhanced antinociceptive action of Vc1.1 in colonic
pathways in a mouse model of CVH suggests it is a novel
candidate for the treatment for CVP associated with IBS.
▸ We show that by reducing nociceptive signalling from the
periphery, Vc1.1 has potential therapeutic value in treating
CVP.
▸ These findings put GABABR agonists in the spotlight as
potential peripheral agents for the treatment of CVP.
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(SNX-482:200 nM) were applied alone, or in combination, at
maximally effective concentrations for 10 min prior to coincu-
bation with Vc1.1 (1000 nM).
CRD and pERK immunohistochemistry
Healthy control or CVH mice received an intracolonic enema
of either saline or Vc1.1 (1000 nM). Ten minutes later, under
anaesthesia, a 4 cm CRD balloon catheter was inserted transan-
ally into healthy or CVH mice.9–11 After regaining conscious-
ness CRD was performed (80 mmHg for 10 s, deflated for 5 s,
repeated five times). Following sacrifice via anaesthetic overdose,
mice underwent fixation by transcardial perfusion and the TL
(T10–L1) and lumbosacral (LS:L6–S1) spinal cord removed and
cryoprotected. Frozen sections were cut and incubated with
monoclonal rabbit anti-phosphorylated MAP kinase ERK 1/2
(pERK) and AlexaFluor-488 was used for visualisation.9–11
Isolation of mouse colonic DRG neurons
TL and LS DRG were removed from healthy control and CVH
mice 4 days after retrograde tracing from the colon with
AlexaFluor-555-conjugated cholera-toxin subunit-B
(CTB-AF555). DRG were dissociated and single or pooled
colonic DRG neurons isolated for downstream mRNA expres-
sion analysis.10
Quantitative-reverse-transcription-PCR
RNA was extracted from either whole human DRG and single
human DRG neurons or mouse whole DRG, pooled colonic
DRG neurons and single colonic DRG neurons from healthy
control and CVH mice using specific isolation kits. QRT-PCR
was performed using either human-specific or mouse-specific
primers for GABABR1, GABABR2, CaV2.2 and
CaV2.3.
10 12 32 34 The comparative cycle threshold method was
used to quantify the abundance of target transcripts to reference
genes.10 12 32 34
Immunohistochemistry
In both perfused-fixed frozen mouse DRG sections and disso-
ciated mouse DRG neurons specific antibodies for GABABR1,
GABABR2, CaV2.2 or CaV2.3 were used to determine the
expression of these targets in retrogradely traced colonic DRG
neurons. Antibody preabsorption and omission of primary anti-
bodies were used as controls (see online supplementary figure
S1). AlexaFluor-488 or AlexaFluor-594 conjugated secondary
antibodies were used for visualisation.
RESULTS
Vc1.1 reduces the excitability of human DRG neurons
To determine if Vc1.1 reduces the excitability of human DRG
neurons we used whole-cell patch clamp recordings to assess
neuronal excitability. Vc1.1 (1000 nM) inhibited a specific
population (40%) of human DRG neurons, which was indicated
by a significant increase in the amount of injected current
required to fire an action potential (figure 1Ai). In this popula-
tion of neurons, Vc1.1 increased the rheobase by 20% com-
pared with control responses (figure 1Aii, B and see online
supplementary figure S2). The average of cell capacitance for all
the recorded human DRG neurons was 131.48±18.03 pF, with
no significant difference in cell capacitance observed between
neurons which were affected by Vc1.1 and those that were not.
To determine if this inhibition was mediated via GABABR or
α9α10-nAChR we used a modified version of Vc1.1 ([P6O]
Vc1.1), which is inactive at the GABABR, but active at the
α9α10-nAChR.35 [P6O]Vc1.1 had no effect on human DRG
neuronal excitability (figure 1C), suggesting Vc1.1 exerts its
inhibitory effects on human DRG neurons via a GABABR mech-
anism. Recent recombinant cell line studies have demonstrated
that the human GABABR is the high affinity (nanomolar) target
for Vc1.1 and that GABABR activation by Vc1.1 causes down-
stream inhibition of the voltage-gated calcium channels CaV2.2
and CaV2.3.
14 In order to determine if the same mechanism
applied in human DRG neurons, we determined the expression
of GABABR and CaV channels in whole TL DRG from five
spinal levels from four human adult donors. We showed that
subunits R1 and R2 for GABABR were expressed as well as
CaV2.2 and CaV2.3 (figure 1D). Expression levels for each of
the targets were remarkably consistent between the different
DRG levels across the four human donors (figure 1D).
Single-cell-RT-PCR of individual human TL DRG neurons
demonstrated that 46% coexpressed GABABR and CaV2.2, the
minimum components required for Vc1.1-induced inhibition
(figure 1E). This was consistent with our patch clamp observa-
tions where 40% of the human DRG neurons tested were inhib-
ited by Vc1.1. Overall, these functional and expression studies
indicate Vc1.1 inhibits human DRG neurons via a
GABABR-mediated mechanism.
Vc1.1 inhibits mouse colonic afferents with greater efficacy
in CVH
Given Vc1.1’s inhibitory actions on human DRG neurons in the
current study and rat somatosensory neurons in previous
studies,16 35 36 we hypothesised Vc1.1 may also inhibit colonic
afferents. To test this hypothesis we performed in vitro single-
unit colonic afferent recordings.9 10 32 33 Specifically, we
recorded from mouse splanchnic nerves, which supply the
mid-to-distal colon and signal predominantly nociceptive infor-
mation,8 33 and the pelvic nerves supplying the colorectum,
which signal a mixture of physiological and nociceptive infor-
mation.8 33 Vc1.1 significantly and dose-dependently decreased
healthy colonic nociceptor activity, with a maximum reduction
in response to mechanical stimulation of 32% at the highest
concentration tested (figure 2Ai). We then asked if these
Vc1.1-induced antinociceptive effects were maintained, or
indeed augmented, in CVH. This question was assessed in a
mouse model where colonic nociceptor mechanical hypersensi-
tivity7–10 and colonic mechanical hyperalgesia and allodynia are
evident long after resolution of TNBS-induced colitis.7 37 38 We
found that colonic nociceptors in the CVH model displayed
pronounced hypersensitivity and that Vc1.1 significantly
reduced nociceptor mechanosensitivity, showing significant
reductions at 100 nM and 1000 nM, with a maximal reduction
of 44% at 1000 nM (figure 2Aii). Overall, Vc1.1’s inhibitory
effect was greatly enhanced in CVH nociceptors compared with
healthy nociceptors (figure 2B, C). We also tested whether the
inhibitory effects of Vc1.1 extended to low-threshold distension
sensitive pelvic afferents and found that Vc1.1 dose-dependently
inhibited pelvic muscular–mucosal afferent responses to circular
stretch in healthy mice (figure 2Di, Fi). The inhibitory effect of
Vc1.1 on pelvic afferents was also enhanced in afferents from
CVH mice (figure 2Dii, E, F).
Vc1.1 reduces in vivo processing of noxious CRD in the
mouse TL and LS spinal cord
Vc1.1 inhibits mouse colonic nociceptors in the splanchnic
pathway and low-threshold distension sensitive afferents in the
pelvic pathway. We therefore hypothesised these actions should
correspondingly reduce signalling of noxious CRD relayed into
the TL and LS spinal cord in vivo. In response to noxious CRD,
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Figure 1 α-Conotoxin Vc1.1 inhibits human dorsal root ganglion (DRG) neurons. (A) (i) Group data showing that Vc1.1 (1000 nM) significantly
increases the rheobase of a subpopulation (40%) of human DRG neurons, indicating Vc1.1 inhibits neuronal excitability and more current is required to
initiate an action potential (**p<0.001, n=10, paired t-test). (ii) In this population of neurons, Vc1.1 increased the rheobase by 20% compared with
baseline response, meaning the neurons are less excitable (**p<0.001). (B) Representative examples of human DRG neuronal responses in the absence
(control solutions) and in the presence of Vc1.1. Note in this example more current is required to fire an action potential from a human DRG neuron in
the presence Vc1.1 (1970 pA) relative to control (1540 pA). (C) [P6O]Vc1.1 (1000 nM), a synthetic analogue of Vc1.1 that does not act at
γ-aminobutyric acid receptor B (GABABR), did not affect human DRG neuronal excitability when expressed as either i) rheobase or ii) % of rheobase
(p>0.05, n=10, paired t-test) indicating Vc1.1 induces its inhibitory effect via the GABABR. (D) Group data of quantitative-reverse-transcription-PCR
analysis from thoracolumbar (T9, T10, T11, T12, L1) DRG from four human adult donors indicating expression of the GABABR subunits R1, R2 and the
voltage-gated calcium channels CaV2.2 and CaV2.3 in human DRG. (E) (i) Examples of gel electrophoresis following single-cell-PCR analysis from
individual human DRG neurons. (ii) Combined analysis of expression and coexpression of GABABR and CaV channels in 39 human DRG neurons. Of
human DRG neurons, 46.2% (18/39) coexpress GABABR and CaV2.2, the minimum components required for Vc1.1-induced inhibition. Combined these
studies indicate Vc1.1 inhibits human DRG neurons via a GABABR-mediated mechanism. GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
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pERK-immunoreactivity (pERK-IR) identifies activated neurons
in the dorsal horn (DH) of the spinal cord.9–11 In healthy mice
given noxious CRD, prior intracolonic administration of
1000 nM Vc1.1 resulted in significantly fewer pERK-IR DH
neurons in both the TL and LS spinal cord (figure 3A–C).
In response to noxious CRD, CVH mice displayed greater
numbers of pERK-IR DH neurons than healthy mice, which
corresponds with the mechanical hypersensitivity of colonic
nociceptors observed in our afferent recording studies. CVH
mice pretreated with intracolonic Vc1.1 displayed significantly
reduced numbers of pERK-IR DH neurons in both the TL and
LS spinal cord following noxious CRD (figure 3D,E), with the
extent of inhibition greater within the TL pathway (figure 3D).
Overall, these results suggest Vc1.1 reduces the signalling of
noxious stimuli from the colon and reduces the CVH observed
in vivo.
Vc1.1-induced inhibition of mouse colonic afferents is
meditated via the GABABR
To elucidate the site and mechanism of action of Vc1.1 in
colonic pathways, we first used [P6O]Vc1.1, which is inactive at
GABABR. As per our recordings in human DRG neurons, [P6O]
Vc1.1 did not inhibit mouse colonic nociceptors (figure 4A),
suggesting that the inhibitory effects of Vc1.1 on colonic affer-
ents are mediated via GABABR.
We then asked if the archetypal GABABR agonist, baclofen,
inhibited colonic nociceptors. Baclofen caused a dose-dependent
inhibition of colonic nociceptors from both healthy (figure 4Bi)
Figure 2 α-Conotoxin Vc1.1 inhibits colonic afferents in ex vivo recordings from healthy and chronic visceral hypersensitivity (CVH) mice. (A)
(i) Vc1.1 significantly inhibits splanchnic colonic nociceptors from healthy mice. Compared with baseline, Vc1.1 at 1000 nM significantly reduced
colonic nociceptor mechanosensitivity (**p<0.01, n=10 afferents, one-way ANOVA, Bonferroni post hoc). (ii) In a model of CVH, nociceptors are
potently and concentration-dependently inhibited by Vc1.1, with significant reductions in mechanical responses at 100 nM and 1000 nM (**p<0.01,
n=10 afferents, one-way ANOVA, Bonferroni post hoc tests). (B) Change in mechanosensitivity induced by Vc1.1 in healthy and CVH nociceptors
compared with their respective baseline responses. Vc1.1 caused significantly more inhibition at 100 nM (**p<0.01) and 1000 nM (*p<0.05) in CVH
nociceptors than healthy nociceptors (healthy: n=10; CVH: n=10, two-way ANOVA, Bonferroni post hoc). (C) Single-unit recordings from the
splanchnic innervation showing inhibition of (i) a healthy nociceptor, and (ii) a CVH nociceptor following application of Vc1.1 (1000 nM). (D) (i)
Vc1.1 inhibited pelvic low-threshold muscular-mucosal afferents from healthy mice. Compared with baseline, significant reductions in the
mechanosensory response evoked by 5 g circular stretch were observed at 100 nM and 1000 nM Vc1.1 (*p<0.05, n=6 afferents). (ii) Low-threshold
muscular–mucosal afferents from CVH mice were also concentration-dependently inhibited by Vc1.1, with significant reductions at 100 nM
(*p<0.05) and 1000 nM (**p<0.01, n=6 afferents). (E) Compared with their respective baseline responses, Vc1.1 causes significantly more inhibition
of muscular–mucosal afferents (*p<0.05 at 1000 nM) from CVH mice (n=6) relative to healthy (n=6) mice. (F) Single-unit recordings from the pelvic
innervation showing inhibition of (i) a healthy low-threshold muscular–mucosal afferent and (ii) a CVH muscular–mucosal afferent following
application of Vc1.1 (1000 nM).
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and CVH (figure 4Bii) mice. Interestingly, and similarly to
Vc1.1, baclofen also inhibited CVH colonic nociceptors to a
greater degree (figure 4C). To confirm that inhibition of colonic
nociceptors by Vc1.1 was mediated by the GABABR, we first
administered the selective GABABR antagonist CGP55845. In
the presence of CGP55845, Vc1.1 no longer inhibited colonic
nociceptors from either healthy (figure 4D) or CVH (figure 4E)
mice. Finally, we confirmed the expression of GABABR subunits
GABABR1 and GABABR2 in colonic DRG neurons by using
immunohistochemistry. More than 80% of colonic DRG
neurons expressed both GABABR1 and GABABR2 subunits
(figure 5A and see online supplementary figure S3). Taken
together, these data suggest that the antinociceptive action of
Vc1.1 on colonic afferents is mediated via GABABR expressed
on colonic afferents.
Coexpression of GABABR and CaV2.2 and CaV2.3 in mouse
colonic DRG neurons
Recent studies in mammalian cell lines show that
Vc1.1-induced inhibition via the GABABR also requires the
presence of either CaV2.2
35 39 or CaV2.3.
40 To examine
whether these channels contribute to the Vc1.1-induced
inhibition of colonic afferents, we determined their expression
profile in both the TL (splanchnic) and LS (pelvic) pathways
innervating the colon. Using qRT-PCR, we found that
GABABR1, GABABR2, CaV2.2 and CaV2.3 were abundantly
expressed in both mouse TL and LS DRG (see online
supplementary figure S4). As colonic DRG neurons represent
only approximately 5% of the neurons in these ganglia, we
performed retrograde tracing to identify colonic innervating
neurons.10 12 34 Single-cell-RT-PCR analysis and
Figure 3 Intracolonic administration of Vc1.1 reduces nociceptive signalling in the dorsal horn (DH) of the spinal cord in response to noxious
colorectal distension (CRD). (A) Noxious CRD (80 mm Hg) in healthy mice results in activation of DH neurons in the thoracolumbar (T10–L1;
splanchnic innervation) and lumbosacral (L6–S1; pelvic innervation) spinal cord, as indicated by pERK-immunoreactivity (pERK-IR). Mice pretreated
with intracolonic Vc1.1 (1000 nM) display significantly fewer DH neurons in the thoracolumbar spinal cord, specifically T11–T12 (**p<0.01) and
T13–L1 (**p<0.01), and the lumbosacral spinal cord (***p<0.001, one-way ANOVA, n=6: healthy+saline, n=6: healthy+1000 nM Vc1.1). (B)
Schematic representation of laminae I–V (LI–LV) in the DH of the spinal cord. (C) (i) Healthy thoracolumbar DH. Left panel: following noxious CRD,
pERK-IR (yellow arrows) neurons were predominantly located in the superficial DH (laminae I) and laminae V. Right panel: in healthy mice
pretreated with Vc1.1 (1000 nM) fewer pERK-IR neurons are evident following noxious CRD. (ii) Healthy lumbosacral DH. Left panel: following
noxious CRD, pERK-IR (yellow arrows) neurons were located in laminae I, II, IV and V. Right panel: healthy mice pretreated with Vc1.1 (1000 nM)
displayed fewer pERK-IR neurons following noxious CRD, particularly within laminae I. (D) In chronic visceral hypersensitivity (CVH) mice, more
neurons are activated by noxious CRD at baseline in the thoracolumbar DH. Pretreatment with intracolonic Vc1.1 (1000 nM) significantly reduces the
number of pERK-IR DH neurons within the T10–T11(*p<0.05), T11–T12 (**p<0.01), T13–L1(**p<0.01) and lumbosacral DH (**p<0.01; CVH
+intracolonic saline: n=6, CVH+intracolonic Vc1.1: n=6). (E) (i) Left panel: in CVH mice, following noxious CRD, pERK-IR neurons in the
thoracolumbar DH were predominantly located in laminae I–II and throughout laminae III–V. Right panel: CVH mice pretreated with Vc1.1
(1000 nM) display fewer pERK-IR neurons following noxious CRD, particularly in the superficial laminae. (ii) CVH mice pretreated with intracolonic
Vc1.1 (1000 nM) display fewer pERK-IR neurons in the lumbosacral DH.
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immunohistochemistry determines the expression and import-
antly the coexpression of these targets specifically within
colonic DRG neurons (figure 5B–D, see online supplementary
figures S5 and S6). Immunohistochemistry demonstrated that
the vast majority of colonic DRG neurons express CaV2.2
(see online supplementary figure S5) and CaV2.3 (see online
supplementary figure S6). Single-cell-RT-PCR confirmed the
majority of colonic DRG neurons expressed GABABR, CaV2.2
and CaV2.3 (figure 5Ci,ii), with 85% of colonic
DRG neurons from healthy and CVH mice coexpressing high
levels of GABABR and CaV2.2 (figure 5Di), with 80% coex-
pressing all three targets, GABABR, CaV2.2 and CaV2.3
(figure 5Dii).
Recent studies indicate there are two isoforms of CaV2.2:
exon-37a and exon-37b.41 42 Using isoform-specific primers and
qRT-PCR from pooled colonic DRG neurons, we found a sig-
nificant increase in the CaV2.2–exon-37a variant in CVH mice
in both TL and LS pathways (figure 5E). This upregulation may
explain the increased efficacy of Vc1.1 in CVH states.
CaV2.2 and CaV2.3 contribute to Vc1.1-mediated inhibition
of mouse colonic nociceptors
Recombinant cell line studies indicate Vc1.1-mediated activation
of GABABR results in the downstream inhibition of both CaV2.2
and CaV2.3 via second messenger pathways.
35 40 To determine
how Vc1.1 inhibits colonic nociceptors, we hypothesised blocking
CaV2.2 and CaV2.3, either alone or in combination with max-
imally effective concentrations of toxin blockers, should also
inhibit mouse colonic nociceptors. Using either a selective CaV2.2
(ω-conotoxin CVID) or CaV2.3 (SNX-482) blocker inhibited
healthy nociceptors (figure 6Ai,Bi, see online supplementary
figures S7A and S8A) and caused greater inhibition of CVH noci-
ceptors (figure 6Aii,Bii, see online supplementary figures S7B and
S8B). In separate experiments a combination of CVID and
SNX-482 caused pronounced inhibition of healthy nociceptors
(figure 6Ci, see online supplementary figure S9A) and even greater
inhibition of CVH nociceptors (figure 6Cii, see online
supplementary figure S9B). Application of Vc1.1 in the presence
of both CVID and SNX-482 had little additional inhibitory effects
in both states (figure 6Ci,ii, see online supplementary figures S9A
and S9B). Overall, these findings suggest Vc1.1-induced activation
of GABABR results in the downstream blockade of CaV2.2 and
CaV2.3, which inhibits colonic nociceptor excitability (figures 6D
and 7).
DISCUSSION
This study provides evidence that the α-conotoxin Vc1.1 inhi-
bits human DRG neurons via activation of the GABABR. It also
demonstrates that the peripheral administration of Vc1.1 in
mice strongly inhibits the processing of nociceptive information
within colonic sensory pathways. We show that both human
DRG neurons and mouse colonic DRG neurons express the
molecular targets of Vc1.1, the GABABR and its downstream
effector channels CaV2.2 and CaV2.3. Correspondingly, we
show that Vc1.1 inhibits colonic afferents in both the splanchnic
and pelvic pathways and that blocking CaV2.2 and CaV2.3
causes inhibition comparable with that of Vc1.1 alone. These
findings highlight the potential therapeutic value of Vc1.1 in the
treatment of CVP.
Figure 4 The inhibitory effect of Vc1.1 on mouse colonic afferents is mediated via the γ-aminobutyric acid receptor B (GABABR). (A) The modified
peptide (P6O)Vc1.1, which is inactive at the GABABR, does not inhibit colonic nociceptors from chronic visceral hypersensitivity (CVH) mice (Not
Significant (NS), n=6 afferents, paired t-test). (B) (i) Application of the GABABR agonist baclofen caused dose-dependent inhibition of healthy
colonic nociceptors, with significant reductions in mechanosensitivity observed at 20 μM (*p<0.05) and 200 μM baclofen (***p<0.001),
respectively. (ii) Similarly, in colonic nociceptors from CVH mice, baclofen caused significant inhibition at 2 μM (*p<0.05), 20 μM (***p<0.001) and
200 μM (***p<0.001), respectively. (C) Change in mechanosensitivity induced by baclofen in healthy and CVH nociceptors, compared with their
respective baseline responses. Baclofen caused significantly more inhibition at 20 μM (*p<0.05) and 200 μM (**p<0.01) in CVH nociceptors
compared with healthy nociceptors (healthy: n=7; CVH: n=6, two-way ANOVA, Bonferroni post hoc). (D) (i) A single dose of Vc1.1 (1000 nM)
caused significant inhibition of colonic nociceptors from healthy mice (***p<0.001, n=10, paired t-test). (ii) Prior incubation with the selective
GABABR antagonist CGP-55845 (5 μM) prevented the Vc1.1-induced inhibition of healthy colonic nociceptors (NS, n=5, one-way ANOVA). (E) (i)
CVH colonic nociceptors were also inhibited by a single high dose (1000 nM) of Vc1.1 (***p<0.001, n=7, paired t-test). (ii) Prior incubation of
CGP-55845 (5 μM) also prevented the Vc1.1-induced inhibition of CVH nociceptors (NS; n=9, one-way ANOVA). ANOVA, analysis of variance.
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Figure 5 Colonic dorsal root ganglion (DRG) neurons express γ-aminobutyric acid receptor B (GABABR) subunits and the voltage-gated calcium
channels CaV2.2 and CaV2.3. (A) Immunohistochemistry for (i) GABABR1 and (iii) GABABR2 in frozen sections of thoracolumbar DRG from mice that
had previously undergone colonic retrograde tracing with CTB-555. A high percentage of traced colonic DRG neurons from both healthy and chronic
visceral hypersensitivity (CVH) mice express (ii) GABABR1 and (iv) GABABR2, respectively (healthy: n=6; CVH: n=5). (B) In separate experiments
healthy and CVH mice underwent retrograde tracing from the colon with CTB-555. After 4 days thoracolumbar DRG neurons were dissociated and
individual colonic DRG neurons were isolated for single-cell-PCR analysis. Gel electrophoresis indicates individual colonic DRG neurons from healthy
and CVH mice and their respective expression of GABABR1, GABABR2, CaV2.2 and CaV2.3. Bath controls, perfusate collected during the isolation of
single cells, show no expression of any of the targets or reference genes. (C) A high proportion of colonic DRG neurons from (i) healthy and (ii) CVH
mice express mRNA for GABABR1, GABABR2, CaV2.2 and CaV2.3. (D) (i) Coexpression of CaV2.2 and GABABR mRNA is found in the majority
(>85%) of thoracolumbar colonic DRG neurons from healthy and CVH mice. (ii) mRNA for the GABABR, CaV2.2 and CaV2.3 are coexpressed in the
majority (80%) of colonic thoracolumbar DRG neurons from healthy and CVH mice. (E) Quantitative-reverse-transcription-PCR from isolated and
pooled (200) colonic DRG neurons shows (i) a significant upregulation of the CaV2.2 exon-37a splice variant in both thoracolumbar and lumbosacral
colonic DRG neurons from CVH mice (*p<0.05; healthy: n=4; CVH: n=4). (ii) There is no overall change in total CaV2.2 (exon-37a+37b) levels.
1090 Castro J, et al. Gut 2017;66:1083–1094. doi:10.1136/gutjnl-2015-310971
Neurogastroenterology
group.bmj.com on June 8, 2017 - Published by http://gut.bmj.com/Downloaded from 
Vc1.1 inhibits sensory DRG neurons, which are the primary
transducers of nociceptive information at the start of the
pain pathway
A crucial finding of this study was Vc1.1’s ability to inhibit a
subpopulation of human DRG neurons. This indicates Vc1.1
has an antinociceptive effect in these neurons, which is a key
discovery for clinical translatability. These findings were comple-
mented with animal studies where we observed significant
Vc1.1-induced inhibition of both colonic nociceptors and low-
threshold stretch sensitive afferents that can encode into the
noxious range. Crucially, we found that these antinociceptive
actions were augmented in a mouse model of CVH. These ex
vivo findings translate in vivo as, in response to noxious CRD,
mice administered intracolonic Vc1.1 have reduced numbers of
activated DH neurons within the TL and LS spinal cord. This
finding indicates, in the presence of Vc1.1, a reduced capacity
to detect and signal nociceptive events from the colon into the
central nervous system. In particular, we observed fewer acti-
vated neurons within the superficial lamina of the DH. This is
the major termination zone for nociceptive afferents and con-
sists of nociception-specific neurons. Importantly, our findings
suggest that Vc1.1 reverses the chronic visceral mechanical
Figure 6 Vc1.1-induced inhibition can be replicated by blocking both CaV2.2 (CVID) and CaV2.3 (SNX-482). (A) (i) In ex vivo preparations colonic
nociceptors from healthy mice are inhibited following incubation of the CaV2.2 antagonist CVID (1 μM), although this effect is not significant,
whereas (ii) chronic visceral hypersensitivity (CVH) colonic nociceptors are significantly inhibited by CVID (*p<0.05, n=10). In both healthy and CVH
colonic nociceptors, the subsequent application of Vc1.1 (1000 nM) in the presence of CVID caused further inhibition (healthy: *p<0.05, n=10; CVH:
**p<0.01, n=10). (B) The CaV2.3 blocker SNX-482 (200 nM) inhibited both (i) healthy (*p<0.05, n=7) and (ii) CVH (*p<0.05, n=5) splanchnic
colonic nociceptor mechanosensitivity. In both healthy and CVH states the subsequent application of Vc1.1 (1000 nM) in the presence of SNX-482
(200 nM) caused further inhibition of healthy colonic nociceptors (**p<0.01, n=7). (C) The combined application of the CaV2.2 and CaV2.3 blockers,
CVID (1 μM) and SNX-482 (200 nM), respectively, significantly inhibits both (i) healthy (*p<0.05, n=8) and (ii) CVH (***p<0.001, n=6) colonic
nociceptors with subsequent application of Vc1.1 (1000 nM) causing little additional inhibition. (D) Inhibition of (i) healthy and (ii) CVH colonic
nociceptors by single doses of Vc1.1 (1000 nM), CVID (1 μM) and SNX-482 (200 nM) or in the presence of a combination of CVID (1 μM) and
SNX-482 (200 nM) expressed as percentage inhibition from healthy nociceptor baseline. CVID causes significantly lesser inhibition than Vc1.1 in (i)
healthy (*p<0.05) and (ii) CVH (**p<0.01) nociceptors. However, blocking both CaV2.2 and CaV2.3 in combination with CVID (1 μM) and SNX-482
(200 nM) causes similar inhibition to Vc1.1 alone.
Figure 7 Proposed antinociceptive
mechanism by which α-conotoxin
Vc1.1 activates γ-aminobutyric acid
receptor B (GABABR). Vc1.1 activates
GABABR expressed on human dorsal
root ganglion (DRG) neurons and on
colonic afferent endings resulting in
Gβγ and c-Src kinase-mediated
inhibition of CaV2.2 and CaV2.3 and
subsequent inhibition of neuronal
excitability. Modified from Adams
et al.14
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hypersensitivity evident in our ex vivo and in vivo studies,
rather than completely blocking nociceptive responses. This is
important as ideal analgesic agents reverse pathological pain,
rather than removing protective pain signalling completely.
Vc1.1 activates GABABR on human DRG neurons and on
mouse colonic afferents to inhibit nociceptive signalling
In this study, we have demonstrated for the first time that Vc1.1
inhibits human DRG neuronal excitability via GABABR activa-
tion. This was evident as [P6O]Vc1.1, which is inactive at
GABABR, does not alter neuronal excitability. Similarly, [P6O]
Vc1.1 did not affect mouse colonic afferents, whereas the select-
ive GABABR antagonist CGP55845 prevented Vc1.1-induced
inhibition of colonic nociceptors, both in healthy and CVH
states. To confirm our proposal that Vc1.1 acts via GABABR, we
used baclofen, the archetypal GABABR agonist, and showed that
it also inhibits colonic nociceptors. Notably, this inhibitory
effect was greater during CVH. The significance of this finding
is fourfold. First, these findings closely match those with Vc1.1
and conclusively demonstrate that activation of GABABR on the
peripheral endings of colonic DRG neurons within the colon
wall results in nociceptor inhibition. Second, although it is
known that baclofen inhibits vagal afferents in the upper gut,43
and low-threshold distension sensitive pelvic colonic afferents,44
it has not been previously shown to inhibit colonic nociceptors,
or afferents in a model of CVH. Third, in rats, both oral and
intravenous administration of baclofen reduces visceral pain-
related pseudo-affective responses to CRD.29 30 Fourth, baclo-
fen also reduces colonic inflammation-induced neuronal activa-
tion within the spinal cord and the brainstem.45 Overall, these
observations are consistent with our current in vitro, ex vivo
and in vivo findings on the antinociceptive actions of Vc1.1. In
response to noxious colonic stimuli, we show inhibition of both
colonic nociceptors and low-threshold afferents and a reduction
in neuronal activation to noxious CRD in the TL and LS DH of
healthy and CVH mice.
Although GABABR have been localised within the rat and
human GI tract,46 47 crucially we demonstrate for the first time,
definitive expression of both GABABR subunits in human DRG
neurons and in colonic DRG neurons from healthy and CVH
mice. Taken together these studies demonstrate that activation
of GABABR on human DRG neurons reduces nociceptive signal-
ling, while activation of GABABR on the peripheral endings of
colonic afferents reduces nociception and visceral pain in both
healthy and hyperalgesic states. These are important findings
and complement studies in other fields of neuroscience,
whereby in pyramidal neurons in the cortex, somatic and den-
dritic GABAB receptors regulate neuronal excitability via differ-
ent mechanisms.48 Specifically, these studies show that activation
of somatic GABAB receptors leads to a reduction in neuronal
output, primarily by increasing the rheobase, whereas activation
of dendritic GABAB receptors blocks burst firing, decreasing
action potential output.48 Our studies recording from the soma
of DRG neurons and primary afferent endings in the colon
support these mechanisms, where we have observed Vc1.1
increasing the action potential rheobase and decreasing action
potential output, respectively.
Vc1.1 as a novel antinociceptive peptide for the treatment
of CVP
Although we have shown that the overall antinociceptive effect
induced by baclofen and Vc1.1 are similar, it is clear from other
studies that Vc1.1 and baclofen act via different mechanisms, in
terms of their binding to GABABR and also their downstream
targets. For example, Vc1.1 does not compete with baclofen for
binding at the ‘Venus fly trap’ on the GABABR, but is proposed
to target the interface between the GABABR subunit ectodo-
mains (figure 7).49 Furthermore, whereas baclofen is able to
inhibit several different neuronal calcium channels, including
CaV2.1, CaV2.2 and CaV2.3, and activate G-protein-coupled
inwardly rectifying potassium channels (GIRK) channels, Vc1.1
is more specific by only acting via CaV2.2 or CaV2.3.
26 35 39 40
Because baclofen crosses the blood–brain barrier, some of its
previously reported antinociceptive effects may be mediated
centrally.50 This presents a problem in terms of its off-target
effects, which include centrally mediated neurological side-
effects, including dizziness.51 In contrast, we show that periph-
eral administration of Vc1.1 ex vivo and in vivo reduces noci-
ceptive signalling, suggesting a peripheral mechanism of action.
Furthermore, as Vc1.1 is a peptide, if delivered peripherally it is
unlikely to cross the blood–brain barrier and therefore may be
less likely to cause central side-effects. Notably, Vc1.1 has been
tested in human clinical trials for treatment of neuropathic
pain.19–21 However, its development was discontinued due to
lack of potency at its (at the time) proposed molecular target,
the human α9α10–nAChR.52 The emergence of an action
mediated via the human GABABR suggests its development for
chronic pain treatment could resume. Given our current finding
of an enhanced Vc1.1 antinociceptive action during CVH, we
suggest it is a novel candidate for the treatment for CVP, par-
ticularly as cyclised versions of Vc1.1 have impressive stability
and are resistant to proteolysis.17
Human DRG neurons and mouse colonic DRG neurons
express CaV2.2 and CaV2.3, the key downstream targets of
GABABR activation by Vc1.1
The GABABR is a G-protein-coupled receptor and therefore
must couple to downstream channels to exert its inhibitory
actions. Previous studies demonstrate Vc1.1-mediated activation
of GABABR is coupled to both CaV2.2 and CaV2.3 via Gβγ and
c-Src kinase second messenger systems.35 40 Cav2.2 channels
mediate the neuronal N-type calcium current,49 whereas CaV2.3
channels typically conduct a small proportion of the whole-cell
calcium current, known as the R-type calcium current.53
Inhibition of CaV2.2, by either gene knockout or selective
channel antagonists, causes analgesia in neuropathic pain
models.49 Notably, CaV channels have been demonstrated in
several studies to contribute to the rheobase of neurons.54 55
While CaV channels have been identified as potential thera-
peutic targets for treating neuropathic pain,56 little is known
about the roles of CaV2.2 and CaV2.3 in visceral pain. Here we
show that the vast majority of colonic DRG neurons express
mRNA and protein for GABABR, CaV2.2 and CaV2.3. Notably,
in colonic DRG neurons from CVH mice, we identified a sig-
nificant upregulation of the CaV2.2 variant exon-37a. Although
the CaV2.2 exon-37a variant is expressed at relatively low levels,
this is an important finding as exon-37a has been reported to be
highly expressed in nociceptors, where it acts as part of a
molecular switch controlling N-type current density and
G-protein-mediated voltage-independent inhibition.41 42 57
Accordingly, upregulation of this variant may contribute to the
processes responsible for mechanical hypersensitivity and neur-
onal hyperexcitability in CVH. Furthermore, this upregulation
may help to explain the increased inhibitory effects of both
Vc1.1 and the CaV2.2 antagonist, ω-conotoxin CVID, in noci-
ceptors from CVH mice. The high expression levels for CaV2.3
in colonic DRG neurons and a considerable inhibitory action of
SNX-482 on colonic nociceptors suggests a key role for CaV2.3
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in colonic pain pathways. Although CaV2.3 channels are present
in some somatic nociceptors58 and can contribute to somatic
pain behaviour via spinal and supraspinal mechanisms,59 60 our
findings are consistent with previous studies suggesting lower
CaV2.3 expression in DRG neurons that innervate the epidermis
than those innervating deep tissues.61 As we could not specific-
ally identify colonic innervating DRG neurons from human
donors, this may explain why we observed less expression of
CaV2.3 in whole human DRG and less human DRG neurons
expressing CaV2.3.
In conclusion, our findings demonstrate an antinociceptive
action for Vc1.1 in human DRG neurons and in colonic sensory
afferents. This antinociceptive action is stronger in a model of
CVH than in healthy mice and is mediated via the
G-protein-coupled receptor, GABABR, which is abundantly
expressed in human DRG neurons and mouse colonic DRG
neurons. Because altered visceral sensory function is a hallmark
of IBS, Vc1.1 represents a potential novel therapy to reduce
nociceptive stimuli from the colon and rectum to the central
nervous system. Our findings highlight the potential therapeutic
value of Vc1.1 and its optimised analogues62 and also identifies
the GABABR as a potential target for the treatment of CVP asso-
ciated with GI disorders.
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